Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2008-04-28 | Dr. Schwieterman has been an independent consultant to biotech and pharmaceutical companies specializing in clinical development since 2002. |
| 2009-04-07 | Dr. Schwieterman is a board-certified internist and a rheumatologist who was formerly Chief of the Medicine Branch and Chief of the Immunology and Infectious Disease Branch in the Division of Clinical Trials at the FDA. |
| 2010-05-28 | Dr. Schwieterman is a board-certified internist and a rheumatologist who was formerly Chief of the Medicine Branch and Chief of the Immunology and Infectious Disease Branch in the Division of Clinical Trials at the FDA. |
| 2011-09-22 | Dr. Schwieterman holds a B.S. and M.D. from the University of Cincinnati. |
| 2012-04-20 | Dr. Schwieterman holds a B.S. and M.D. from the University of Cincinnati. |
| 2013-06-13 | Dr. Schwieterman holds a B.S. and M.D. from the University of Cincinnati. |
| 2014-04-30 | Dr. Schwieterman holds a B.S. and M.D. from the University of Cincinnati. |
| 2015-04-17 | Dr. Schwieterman is a board-certified internist and a rheumatologist. Dr. Schwieterman was previously a part-time employee of Perceptive Advisors, LLC, a hedge fund based in New York, NY. |
| 2016-04-25 | Dr. Schwieterman is a board-certified internist and a rheumatologist. Dr. Schwieterman was previously a part-time employee of Perceptive Advisors, LLC, a hedge fund based in New York, NY. From 2009 to 2014, Dr. Schwieterman was the Chief Medical Officer of Chelsea Therapeutics, Inc., a publicly traded biopharmaceutical development company. |
| 2017-04-26 | Dr. Schwieterman holds a B.S. and M.D. from the University of Cincinnati and has experience as a board-certified internist and rheumatologist. |
| 2018-05-07 | Dr. Schwieterman is a board-certified internist and a rheumatologist. Dr. Schwieterman was previously a part-time employee of Perceptive Advisors, LLC, a hedge fund based in New York, NY. From 2009 to 2014, Dr. Schwieterman was the Chief Medical Officer of Chelsea Therapeutics, Inc. |
Data sourced from SEC filings. Last updated: 2025-10-11